However, most ovarian and breast cancers, and nearly all other types of cancer, have normal BRCA1 and BRCA2; and even in BRCA1/2-mutant tumors, responses to PARPi are heterogeneous and initially responsive cancers eventually develop PARPi resistance. This evidence concerns the gene BRCA2 and breast carcinoma.